ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Beh...
| Model | Near-Term (0-3 mo.) | Mid-Term (3-12 mo.) | Long-Term (1-5 yr.) |
|---|---|---|---|
| Deepseek | Hold | Buy | Buy |
| OpenAI | Buy | Buy | Strong Buy |
| Gemini | Buy | Buy | Hold |
| Grok | Buy | Hold | Buy |
Current price is slightly above the fifty and two hundred day averages, indicating stability but limited near-term upside.
The healthcare sector's resilience and ABBV's fair valuation support a positive outlook for the mid-term.
ABBV's strong market position in healthcare and ongoing innovation support long-term growth.
Current price above moving averages suggests upward momentum in the short term.
Low beta and solid PEG ratio suggest stability and growth potential.
Healthcare sector stability and market cap provide long-term security, but monitor growth.
ABBV shows a stable upward trend and favorable valuation metrics.
Continued growth expected with strong sector fundamentals.
Long-term potential driven by robust pipeline and market position.
Current price above moving averages indicates bullish momentum. Short-term upside potential is likely.
Stable fundamentals but limited growth catalysts expected. Monitor for sector trends and earnings.
Strong fundamentals and low beta suggest long-term stability. Healthcare sector likely to remain resilient.
